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ABSTRACT
Introduction: The increasing financial burden
associated with diabetes treatment presents a
challenge to healthcare systems worldwide.
Recently, clinical guidelines have focussed on
patients with type 2 diabetes (T2D) and estab-
lished cardiovascular disease (CVD) and rec-
ommend a sodium-glucose co-transporter 2
(SGLT2) inhibitor or a glucagon-like peptide 1
(GLP-1) receptor agonist as second-line
treatment after metformin or independently of
baseline glycated haemogloblin A1c (HbA1c). In
Danish clinical guidelines, empagliflozin and
liraglutide are highlighted owing to their posi-
tive impact on mortality. Thus, this study aimed
to assess the cost-effectiveness of empagliflozin
plus standard of care (SoC) versus liraglutide
plus SoC in Danish patients with T2D and
established CVD using a lifetime and 5-year
horizon.
Methods: The IQVIA Core Diabetes Model
(CDM) was calibrated to reproduce the clinical
event rates observed in the cardiovascular out-
come trial EMPA-REG OUTCOME. Network
meta-analysis provided the relative risks for
cardiovascular outcomes with empagliflozin
versus liraglutide. Microvascular outcomes were
predicted by standard CDM risk equations. The
relative treatment effect was assumed for 9 years
after which treatment was switched to basal-
bolus therapy. The CDM was populated with
Danish costs of events and drug costs at price-
level 2019. Discounting of 4% was applied.
Results: Over a lifetime horizon, CDM pro-
jected 9.858 and 9.667 life years, 6.162 and
5.976 quality-adjusted life years (QALY) and
DKK 478,026 (€64,079) and DKK 500,025
(€67,027) in total costs for empagliflozin plus
SoC and liraglutide plus SoC, respectively. For a
5-year horizon, the results were 4.189 and 4.140
life years, 2.746 and 2.655 QALY, as well as
DKK 123,413 (€16,543) and DKK 161,783
(€21,687), respectively. Empagliflozin was the
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dominant treatment alternative. Sensitivity
analyses showed the robustness of these results.
Conclusion: The cost-effectiveness analysis
suggests that empagliflozin plus SoC is domi-
nant compared to liraglutide plus SoC in Den-
mark over both lifetime and 5-year horizons.
Keywords: Cardiovascular outcomes; Cost-
effectiveness; Diabetes type 2; Empagliflozin;
Liraglutide
Key Summary Points
Why carry out this study?
International clinical guidelines
recommend an SGLT2 inhibitor or a GLP-
1 receptor agonist as second-line
treatment after metformin or
independently of baseline HbA1c in
people with type 2 diabetes and
established cardiovascular disease. In
Danish clinical guidelines, empagliflozin
and liraglutide are highlighted owing to
their positive impact on mortality.
Clinical guidelines, however, do not
consider costs. Thus, this study aimed to
assess the cost-effectiveness of
empagliflozin versus liraglutide.
What was learned from the study?
This study showed that empagliflozin was
cost effective compared to liraglutide in a
Danish healthcare setting in the
management of patients with type 2
diabetes and established cardiovascular
disease.
Considerable cost savings were associated
with the use of empagliflozin, as well as a
small QALY gain mainly driven by a small
estimated gain in survival.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14077133.
INTRODUCTION
The global economic burden of diabetes is
staggering [1]. In the USA alone, the American
Diabetes Association estimated the total costs
associated with patients diagnosed with type 2
diabetes mellitus (T2D) to be $327 billion in
2017 and care for people with diabetes now
accounts for one in four healthcare dollars in
the USA [2]. In Denmark, these costs are cur-
rently estimated to be €4.27 billion and expec-
ted to rise because of a number of factors
including a rapidly increasing population with
T2D [3, 4]. The cost of diabetes medication is
now the largest item on the primary care drug
budget in Denmark [5]. T2D is a progressive and
chronic disease requiring treatment intensifica-
tion over time focussed on maintaining an
adequate glycaemic control while avoiding
hypoglycaemia [6–9]. The ultimate treatment
goals for T2D are to prevent or delay costly
complications as well as maintaining quality of
life [6]. Modern care for T2D entails a multi-
factorial approach comprising the minimiza-
tion of additional risk factors for both micro-
and macrovascular diabetes-related complica-
tions. Therefore, the impact of interventions
reducing cardiovascular (CV) risk is an increas-
ingly important consideration when choosing
therapies.
Because patients with diabetes have an
increased risk of cardiovascular disease (CVD),
as well as safety signals seen with some previous
diabetes medications, in 2008 the US Food and
Drug Administration (FDA) determined that
concerns about CV risk should be more thor-
oughly addressed during diabetes drug devel-
opment [10]. This decision was followed by the
European Medicines Agency (EMA) in 2012
[11]. Consequently, these agencies required the
industry to conduct post-marketing
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cardiovascular outcome trials (CVOT) to docu-
ment the safety of all novel diabetes therapies
[10, 11]. The first CVOTs completed after 2008
on new glucose-lowering agents, such as the
dipeptidyl peptidase 4 (DPP4) inhibitors sax-
agliptin, alogliptin and sitagliptin as well as the
glucagon-like peptide 1 (GLP-1) receptor ago-
nist lixisenatide, were all shown to be safe with
respect to CV outcomes in high CV risk popu-
lations [12, 13]. The EMPA-REG OUTCOME trial
with the sodium-glucose co-transporter 2
(SGLT2) inhibitor empagliflozin was the first
CVOT to not only show non-inferiority but also
to significantly reduce CV risk compared to
placebo, as shown by the composite primary
and secondary outcomes, as well as a composite
outcome of hospitalization due to heart failure
(HF) and CV death [14, 15]. Moreover, the
LEADER trial showed that liraglutide was not
only safe but also capable of reducing CV risk
and the incidence of CV death [16, 17].
In people with T2D and established CVD,
clinical guidelines now recommend an SGLT2
inhibitor or GLP-1 receptor agonist as second-
line treatment after metformin [7, 8] indepen-
dently of baseline glycated haemogloblin A1c
(HbA1c) [6, 9]. These clinical guidelines, how-
ever, do not consider cost. The treatment rec-
ommendations are based on systematic
literature reviews of clinical evidence only, and
do not include economic evidence based on
costs and cost-effectiveness.
Health economic evaluations should be
considered as valuable information for decision-
makers in healthcare because they provide data
on the opportunity costs of alternative treat-
ment strategies [18]. Resources in healthcare are
limited, and every decision about using scarce
resources on a specific treatment is associated
with an opportunity cost which reflects the
health benefit foregone (i.e. the health benefit
that could have been obtained if the resources
were used otherwise). Internationally, there is
no consensus on how to incorporate economic
considerations pertaining to the cost of diabetes
into clinical recommendations regarding treat-
ment strategy. The cost of diabetes has been
described as the elephant in the room, ‘‘impos-
sible to miss, but frequently ignored’’ [19].
In Danish clinical guidelines, empagliflozin
and liraglutide are highlighted owing to their
positive impact on mortality. The aim of the
present analyses was to assess the cost-effec-
tiveness of empagliflozin versus liraglutide in




The IQVIA Core Diabetes Model (CDM) CVO
version 9.0 was used to estimate the cost and
quality-adjusted life years (QALYs) with respect
to empagliflozin plus standard of care (SoC)
versus liraglutide plus SoC in patients with T2D
and established CVD. The primary outcome of
the model was the incremental cost-effective-
ness ratio (ICER). A Danish health sector per-
spective was used for a long-term (50 years) and
short-term (5 years) time horizon. Future costs
and QALYs were discounted with a rate of 4% as
recommended by the Danish guidelines for
health economic evaluation of pharmaceuticals
[20]. All prices are stated in Danish krone (DKK)
price-level 2019 excluding value added tax
(VAT). Main results are also presented in euros
(DKK 746 = €100).
The CDM is a web-based simulation model
that determines the long-term health outcomes
and economic consequences associated with
different interventions in patients with dia-
betes. It has been used in more than 100 peer-
reviewed publications and a significant number
of reimbursement submissions worldwide. The
structure of the CDM and the most recent val-
idation are described in detail elsewhere
[21, 22]. More information on CDM version 9.0
is available online (http://www.core-diabetes.
com/). The CDM is a non-product-specific
microsimulation tool that models the effect of
glucose monitoring, diabetes therapies and
treatment strategies on disease progression and
outcomes. Disease progression is based on a
series of interdependent Markov submodels that
simulate progression of disease-related compli-
cations (angina, myocardial infarction, conges-
tive heart failure, stroke, peripheral vascular
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disease, diabetic retinopathy, macular oedema,
cataract, hypoglycaemia, ketoacidosis,
nephropathy and end-stage renal disease, neu-
ropathy, foot ulcer, amputation) and non-
specific mortality. Each submodel uses time-,
state- and diabetes type-dependent probabilities
derived from published sources. The use of
tracker variables bypasses the memoryless
properties of standard Markov models. The
model facilitates interconnectivity and interac-
tion between the modelled complications, rep-
resenting the complex and varied sequelae of
the disease.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Clinical Data
The model calculations assume a cohort of
individuals with T2D and baseline characteris-
tics replicating the patients in the EMPA-REG
OUTCOME trial (Table 1).
Data on treatment effects of empagliflozin
and liraglutide on risk factors for CVD (i.e.
annual progression of risk factors HbA1c, body
mass index (BMI), blood pressure, lipids) were
taken directly from the EMPA-REG OUTCOME
[14, 15] and LEADER trials [16, 17].
Data on 3-year event rates for empagliflozin
plus SoC were taken directly from the EMPA-
REG OUTCOME trial. Event rates for liraglutide
were calculated using the relative risks (RR)
from an indirect treatment comparison (net-
work meta-analysis) (Table 2) [23].
The CDM calibration process ensures that
the CDM can replicate the trials’ outcomes
accurately at 3 years, which is a joint time point
shared by the clinical trials, and has been
described before [24]. In the CDM, different risk
equations were tested and the United Kingdom
Prospective Diabetes Study (UKPDS) 82 was
found to be the best fit to predict the 3-year
clinical outcomes. The outcomes used to cali-
brate the predictions were primary and sec-
ondary myocardial infarction (MI), primary and
secondary stroke, hospitalization for angina,
hospitalization for heart failure, CV death, non-
CV death, microalbuminuria and end-stage
renal disease. During this calibration, RR
adjustments for outcomes were estimated by
successively running the model until the CDM-
predicted outcomes matched the observed ones
closely. The 3-year observed CV events for
empagliflozin plus SoC versus liraglutide plus
SoC are presented in Table 3.
The UKPDS 82 combined mortality approach
was also chosen for the calculation of mortality
and thus country-specific life tables were not
needed.
Treatment Intensification and Long-Term
Risks
Since empagliflozin and liraglutide are both
relatively new therapies, data on the long-term
duration of treatment effect is currently lacking,
and therefore assumptions were necessary. The
drug-specific treatment effects on hard out-
comes were assumed for 9 years (corresponding
to the point at which HbA1c reached 8.5% in
the empagliflozin arm and treatment was esca-
lated). After this period, all patients were
assumed to switch therapy and receive basal-
bolus insulin as next line of therapy. The
UKPDS 82 risk equations were applied to predict
future CV events based on co-existing risk
factors.
Costs and Management
Unit costs for treatment, including empagli-
flozin and liraglutide, were obtained from
Medicinpriser.dk in November 2019 and corre-
sponded to the average of the lowest unit cost
for each drug during six price periods from
9 September 2019 to 18 November 2019. Phar-
macy purchase price excluding VAT and phar-
macy fee (In Danish: Apotekets Indkøbspriser,
AIP) were used. For empagliflozin, the price per
day was DKK 11.49 corresponding to an annual
cost per patient of DKK 4195.38. For liraglutide,
aligned with the LEADER study [17], the daily
dose was 1.8 mg corresponding to a daily price
of DKK 34.29 per day and an annual cost of
DKK 12,526.10.
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Costs of CV complications were obtained
from a report prepared by the Danish national
institute VIVE [25]. This report used the unique
Danish registries based on personal identifica-
tion numbers (CPR) to identify the average real-
world cost of patients with a specific CV event
Table 1 Baseline characteristics of the EMPA-REG OUTCOME study
Patient characteristics Value
Age; mean (SD) 63.1 (8.6)
% male; n (%) 72%
Currently smoking 13%
Ex-smoker 46%
Time since diagnosis of diabetes
B 5 years 18%
[ 5 years to B 10 years 25%
[ 10 years 57%




History of stroke 23%
Peripheral occlusive arterial disease 21%
Key baseline laboratory test
HbA1c (%), mean (SD) 8.1 (0.8)
Fasting plasma glucose (mmol/L), mean (SD) 8.5 (2.4)
Body mass index (BMI) (kg/m2), mean (SD) 30.6 (5.3)
Weight (kg), mean (SD) 86.4 (18.9)
Waist circumference (cm), mean (SD) 105 (14)
Systolic blood pressure (SBP) (mmHg), mean (SD) 135 (17)
Diastolic blood pressure (DBP) (mmHg), mean (SD) 77 (10)
TC (mmol/L; mg/dl); mean (SD) 4.2 (1.1); 162.4 (42.5)
LDL (mmol/L; mg/dl); mean (SD) 2.2 (0.9); 85.1 (34.8) mg/dl
HDL (mmol/L; mg/dl); mean (SD) 1.2 (1.4); 46.4 (54.14) mg/dl
Triglycerides (mmol/L; mg/dl); mean (SD) 1.9 (1.4); 168.3 (124) mg/dl
SD standard deviation, nF nonfatal, MI myocardial infarction, CAD coronary artery disease, HbA1c glycated haemoglobin,
CABG coronary artery bypass graft surgery, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP
diastolic blood pressure, BMI body mass index, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein
cholesterol
Source: Table 1 in Zinman et al. 2014 [14]
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compared to a matched control group with no
such event.
The costs of treating other diabetes-related
complications (in the year of the event) and the
annual follow-up costs (applied in each year of
the simulation subsequent to the first event)
were identified through literature reviews and
inflated using the consumer price index pub-
lished by Statistics Denmark. More information
on the applied unit costs for clinical manage-
ment and complications is available in the
supplementary material.
Utilities
To estimate the expected QALY gain of each
treatment pathway, the CDM uses a
comprehensive set of utility weights for each
model state [26]. Utilities are assessed on a scale
from 0 to 1, where 0 represents death (no
quality of life) and 1 indicates a healthy person
without complications. Disutilities due to ill-
ness are values in the range - 1 to 0, and
therefore cause the quality of life utility to
either decrease or remain constant. Following
an event, patients change state and the new
state is associated with different state utilities.
Quality of life values are then estimated for
every hypothetical patient in each year of the
simulation and used to estimate the average
quality-adjusted life expectancy. For all simula-
tions, the minimum approach method was
applied to calculate the quality-adjusted life
utility. The values used for this analysis and

























MI myocardial infarction, HF heart failure
Source: Balijepalli et al. 2018 [23]
Table 3 CDM predicted 3-year cumulative incidence (%) outcomes for empagliflozin and liraglutide compared to EMPA-
REG OUTCOME trial and indirect comparison results
Empagliflozin Liraglutide
EMPA-REG observed Model predicted Estimated by IDC Model predicted
Death from any cause 5.82 5.78 7.28 7.24
Death from cardiovascular causes 3.72 3.68 4.65 4.63
MI 5.04 5.05 5.09 5.08
Angina 3.00 3.01 3.00 3.06
Stroke 3.69 3.70 2.72 2.71
HF 2.82 2.83 3.76 3.79
MAU 75.75 75.86 75.75 76.76
GRP 12.54 12.34 12.54 9.17
ESRD 0.3 0.3 0.3 0.28
MI myocardial infarction, HF heart failure, MAU microalbuminuria, GRP gross proteinuria, ESRD end-stage renal disease,
IDC indirect comparison (network meta-analysis)
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references are available in the supplementary
material.
Sensitivity Analyses
The CDM uses Monte Carlo simulations toge-
ther with a non-parametric bootstrapping
approach to capture parameter uncertainty
throughout the model, so that the imprecision
of cost-effectiveness results can be assessed.
Furthermore, several one-way and scenario
analyses were conducted including the exclu-
sion of insulin costs from treatment costs and
changes in the number of years people with
T2D receive empagliflozin or liraglutide after
which point patients switch to basal-bolus
therapy.
RESULTS
Empagliflozin provides additional life years and
QALYs compared to liraglutide both in a life-
time and 5-year horizon (Table 4). In terms of
total costs, liraglutide is more expensive com-
pared to empagliflozin. No incremental cost-
effectiveness ratios (ICERs) were calculated as
empagliflozin is a dominant treatment alterna-
tive (both lower cost and higher QALYs).
Treatment costs were higher for liraglutide
than for empagliflozin. Part of this was offset
over time by higher complication costs in
patients receiving empagliflozin compared to
liraglutide (Fig. 1). Thus, the estimated savings
from empagliflozin were higher in the 5-year
than lifetime horizon. As a result of the longer
survival with empagliflozin and consequent
prolonged exposure to diabetes complications,
complication costs were higher in the empagli-
flozin plus SoC arm than in the liraglutide plus
SoC arm. The probabilistic sensitivity analysis
(lifelong time horizon) showed that empagli-
flozin is cost-effective in comparison to liraglu-
tide in more than 78% of the simulations for a
willingness to pay threshold of DKK 357,100 per
QALY (1 time Gross Domestic Product (GDP)
per capita) (Figs. 2 and 3). Dominance was
observed in 59% of the simulations. All one-way
and scenario analyses confirmed the robustness
of the results (Supplementary material Appen-
dix 1 table 10).
Total costs for the 50-year period were
DKK 478,026 for empagliflozin plus SoC and
DKK 500,025 for liraglutide plus SoC per
patient. For the 5-year period, total costs were
DKK 123,413 for empagliflozin plus SoC and
DKK 161,783 for liraglutide plus SoC per patient
(Fig. 1).
DISCUSSION
Overall, this study demonstrates the cost-effec-
tiveness of empagliflozin compared to liraglu-
tide in the management of patients with T2D
and established CVD for both a lifetime and
5-year horizon. Results show considerable cost
savings associated with the use of empagli-
flozin, as well as a small QALY gain mainly
driven by a small estimated gain in survival.
Modelling cost-effectiveness using CVOTs is
the most widely used approach for incorporat-
ing evidence of drug-mediated cardioprotection
Table 4 Cost-effectiveness results
Lifetime horizon 5-year horizon
Empagliflozin Liraglutide Empagliflozin Liraglutide
LY 9.858 9.667 4.189 4.067
QALY 6.162 5.976 2.746 2.655
Total cost 478,026 500,025 123,413 161,783
ICER (DKK/QALY) Dominant Dominated Dominant Dominated
LY life years, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
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in people with T2D [27]. This approach gener-
ally has advantages compared to other mod-
elling approaches; however, there are also
several limitations.
The clinical data considered in the current
analyses do not come from head-to-head com-
parisons, but from an indirect comparison
between the LEADER and the EMPA-REG OUT-
COME trials [23]. Indirect comparison for rela-
tive risks is limited by substantial heterogeneity.
In particular, because the trials differ by study
population and differences in SoC.
Another limitation is that the current anal-
ysis uses the UKPDS 82 risk equations to predict
lifetime health outcomes after treatment
switch. The UKPDS 82 was applied because the
calibration exercise showed that this option
provided the best prediction of the EMPAREG-
OUTCOME trial outcomes. Treatment switch
was assumed to happen after 9 years in the
model. Sensitivity analysis up to 13 years for
liraglutide did not alter the results.
Furthermore, the CDM calculations are
based on assumptions on utilities and costs.
Fig. 1 Total costs per individual (DKK)*. T2D type 2
diabetes, CVD cardiovascular disease, SoC standard of
care, NSHE nonsevere hypoglycemic events, SHE severe
hypoglycemic events. *Total cost per individual (DKK) is
available in Table 9 in the supplementary material
Fig. 2 ICER scatter plot, empagliflozin vs. liraglutide
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Utility data were not trial specific, but instead
taken from published literature for a general
T2D population. Therefore, utility data specific
to patients with T2D and established CVD were
not available. However, this utility data set has
previously been established as a good reference
set of utility values in accordance with health
economic guidelines [26]. Cost data on comor-
bidity were similar to those assumptions used in
economic evaluations of orally administered
semaglutide [28] except for CVD costs, where
new evidence has been published [25].
Our results generally align with other find-
ings in the literature; however, only a few
health economic studies have so far compared
empagliflozin with liraglutide in people with
T2D and established CVD. A US study on the
economic aspects of empagliflozin versus
liraglutide for prevention of CV mortality con-
cludes that empagliflozin prescribed for pre-
venting CV death in patients with T2D and
high CV risk seems to be a major cost-saving
strategy compared with liraglutide [29]. A UK
study on the cost-effectiveness of empagliflozin
versus liraglutide based on CVOT finds empa-
gliflozin plus SoC to be dominant compared to
liraglutide plus SoC from the UK NHS perspec-
tive [24]. The current study was an adaptation
of this UK study to a Danish setting. More
details on the methodology can be found in this
publication. A systematic review on the phar-
macoeconomic evaluation of SGLT2 inhibitors
for the treatment of T2D finds that, in studies
based on data from EMPA-REG OUTCOME,
treatment with empagliflozin generally appears
to be especially cost-effective in those with the
pre-existing CVD. This review, however, does
not include GLP-1 receptor agonists or DPP4
inhibitors [30].
The Danish payer requests information on
total cost differences at 5 years [31]. Total costs
for the 5-year period showed a difference of
DKK 38,370 (€5143) per patient or - 24% with
empagliflozin plus SoC versus liraglutide plus
SoC (Fig. 3). Even taking a life-long perspective
(50 years) where the higher life expectancy with
empagliflozin plus SoC resulted in a higher
number of complications, empagliflozin plus
SoC still had lower total costs than liraglutide
plus SoC.
According to a recent registry study, 24.4%
of Danes with T2D have established CVD [32],
which corresponds to roughly 60,000 people
[33]. Of these, 75% are currently estimated to
not be treated with either an SGLT2 inhibitor or
a GLP-1 receptor agonist despite the recom-
mendation in Danish clinical guidelines (Data



























Willigness to pay (DKK)
Fig. 3 Cost-effectiveness acceptability curve of empagliflozin versus liraglutide
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future treatment strategy may have significant
impact on the regional budgets, and that fur-
ther budget impact analysis is warranted.
Health economic evaluations provide
important input for decision-makers in health-
care as they yield information on the opportu-
nity costs of alternative treatment strategies.
Since 2017, the Danish Medicines Council has
published recommendations for hospital drug
use based on both clinical and economic evi-
dence of the costs and consequences with
respect to alternative treatments [34]. For pri-
mary care prescription medicine, however, the
Danish reimbursement system still does not
require pharmaceutical companies to submit
economic evaluations. Besides voluntary price-
cap agreements, there is free pricing on primary
care prescriptions drugs in Denmark. Nonethe-
less, the recent years’ development in the mar-
ket for hospital drugs shows an increasing focus
among Danish decision-makers on pharmaceu-
tical prices and consumption. It seems likely
that this focus will eventually also be directed
towards the market for primary care prescrip-
tion medicine. The market for primary care
prescription medicine constitutes approxi-
mately 40% of the annual costs of medicine in
Denmark, with patients paying approximately
30% of the bill [34].
Further real-life studies focussing on the
costs and consequences of treatment of patients
with T2D and established CVD should be
conducted.
Limitations of the Current Study
These main limitations in the study are (1) the
lack of a head-to-head comparison between the
two drugs, (2) the use of published risk equa-
tions to predict long-term costs and health
outcomes and (3) the use of assumptions taken
from published literature regarding unit costs
and utility values for different health states.
CONCLUSION
This study demonstrates that empagliflozin is a
dominant treatment compared to liraglutide in
the management of T2D patients with estab-
lished CVD in a Danish setting.
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